RxDoctor Payments Data

Qanwarpartap Sidhu, MD

Dermatology · Lancaster, CANPI 1093341968

Payments from drug & device makers

$519in general payments, 2019–2025

Across 18 payments — averaging $28.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Stryker$171
  • Lilly USA, LLC$58
  • GSK$52
  • Pfizer$30
  • Boehringer Ingelheim$28
  • Corcept Therapeutics$25
  • plus $155 from 8 others

What the payments were for

  • Food & beverage$519100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$519 in reported general payments places this provider in the 30th percentile of 1,875 dermatology providers in California.

See all dermatology providers in California

Medicare billing

Part B allowed, 2024
$53,208
Medicare patients
203
Services billed
534

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin37$42,497
OzempicSemaglutide26$23,160
RybelsusSemaglutide12$17,349
EliquisApixaban15$15,001
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$13,373
MounjaroTirzepatide13$13,186
Levothyroxine Sodium74$1,776
SynthroidLevothyroxine Sodium12$1,300
Albuterol Sulfate HfaAlbuterol Sulfate35$1,115
Atorvastatin Calcium88$893
Amlodipine-ValsartanAmlodipine Besylate/Valsartan12$806
Metoprolol Succinate41$789
Valsartan23$732
Celecoxib12$706
Ezetimibe22$576

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$28$42,49737 claims
Novo NordiskOzempic, Rybelsus$24$40,51038 claims
PfizerEliquis$30$15,00115 claims
GSKTrelegy Ellipta$52$13,37322 claims
Lilly USA, LLCMounjaro$58$13,18613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 1,875 dermatology providers in California.

Other dermatology in Lancaster

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →